Skip to content

US · AIDX · MEDICAL - CARE FACILITIES

20/20 Biolabs Inc. (AIDX) intrinsic value and stock valuation

$0.16as of 2026-11-21 · Mkt cap 2.49M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

20/20 Biolabs Inc. DCF and intrinsic value

InvestorsCraft values AIDX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AIDX’s statements →

20/20 Biolabs Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Care Facilities Gaithersburg, MD 20877 2020biolabs.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$2.05M-2.5% 5y CAGRd
20162025
Net income
-$-3.74M
20162025
Free cash flow
-$-1.92B
20162025
Total equity
-$-19.23M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$2.05M$1.75M$1.42M$11.1M$9.62M
Operating income-$-3.33M-$-5.66M-$-6.36M$1.68M$1.94M
Net income-$-3.74M-$-5.55M-$-6.39M$2.19M$2.07M
EPSd-$-597.44K-$-1.16M-$-1.34M$230.8K$218.8K
Operating cash flow-$-1.92B-$-2.6M-$-4.63M$5.8M-$-1.07M
Capital expenditure$0.00$0.00-$-10K-$-260K-$-230K
Free cash flow-$-1.92B-$-2.6M-$-4.64M$5.54M-$-1.3M
Total assets$4.14B$3.61M$6.37M$12.2M$10.3M
Total debt$1.28B$1.51M$2.07M$2.41M$2.35M
Net debt$258M-$-270K-$-2.02M-$-6.39M-$-1M
Total equity-$-19.23M$1.53M$4.29M$9.37M$6.89M
Cash and short-term investments$1.03B$1.78M$4.09M$8.81M$3.35M
Income statement
20252024202320222021
Revenue$2.05M$1.75M$1.42M$11.1M$9.62M
Cost of revenue$1.44M$1.39M$1.32M$5.94M$4.93M
Gross profit$600K$360K$110K$5.12M$4.69M
Research and development expenses$590K$1.26M$1.41M$120K$190K
Selling, general and administrative expenses$3.34M$4.76M$5.06M$3.32M$2.56M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$3.94M$6.02M$6.47M$3.44M$2.75M
Cost and expenses$5.38M$7.41M$7.79M$9.38M$7.68M
Interest income$20K$80K$210K$70K$0.00
Interest expense$160K$10K$30K$20K$10K
Depreciation and amortization$80K$140K$170K$290K$120K
Ebitda-$-3.5M-$-5.53M-$-6.19M$1.97M$2.07M
Operating income-$-3.33M-$-5.66M-$-6.36M$1.68M$1.94M
Total other income/expenses, net-$-410K$110K-$-30K$510K$130K
Income before tax-$-3.74M-$-5.55M-$-6.39M$2.19M$2.07M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-3.74M-$-5.55M-$-6.39M$2.19M$2.07M
Weighted average shares outstanding$6.26M$4.8M$4.77M$4.76M$4.73M
Weighted average diluted shares outstanding$6.26M$4.8M$4.77M$9.49M$9.46M
Balance sheet
20252024202320222021
Cash and short-term investments$1.03B$1.78M$4.09M$8.81M$3.35M
Net receivables$200M$140K$70K$760K$4.22M
Inventory$116.2M$50K$60K$90K$250K
Total current assets$1.47B$2.03M$4.3M$9.73M$7.94M
Property, plant and equipment, net$662M$890K$1.18M$1.67M$1.68M
Goodwill and intangible assets$202.3M$500K$530K$730K$580K
Long-term investments$0.00$30K$0.00$0.00$0.00
Total non-current assets$2.67B$1.58M$2.07M$2.48M$2.33M
Total assets$4.14B$3.61M$6.37M$12.2M$10.3M
Accounts payable$868.5M$370K$360K$460K$830K
Short-term debt$176M$170K$160K$200K$150K
Deferred revenue$414.9M$470K$250K$320K$150K
Total current liabilities$2.46B$1.36M$1.01M$1.63M$2.25M
Long-term debt$1.11B$1.35M$1.91M$2.21M$2.21M
Deferred revenue, non-current$0.00$50K$0.00$0.00$0.00
Total non-current liabilities$1.11B$720K$1.07M$1.21M$1.13M
Capital lease obligations$0.00$670K$840K$1M$1.13M
Total liabilities$1.69B$2.08M$2.08M$2.84M$3.38M
Common stock$54.4M$50K$50K$50K$50K
Retained earnings-$-33.25B-$-29.51M-$-23.96M-$-17.57M-$-19.75M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-19.23M$1.53M$4.29M$9.37M$6.89M
Total investments$0.00$30K$0.00$0.00$0.00
Total debt$1.28B$1.51M$2.07M$2.41M$2.35M
Net debt$258M-$-270K-$-2.02M-$-6.39M-$-1M
Cash flow statement
20252024202320222021
Net income-$-3.74B-$-5.55M-$-6.39M$2.19M$2.07M
Depreciation and amortization$0.00$140K$170K$290K$120K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$0.00$620K$230K$3.12M-$-3.31M
Accounts receivable$0.00-$-70K$700K$3.48M-$-4.01M
Inventory$0.00$10K$30K$160K-$-140K
Accounts payable$0.00$10K-$-100K-$-250K$360K
Net cash provided by operating activities-$-1.92B-$-2.6M-$-4.63M$5.8M-$-1.07M
Investments in property, plant and equipment$0.00$0.00-$-40K-$-470K-$-230K
Acquisitions, net$0.00$0.00$0.00$10K$0.00
Net cash used for investing activities$0.00$0.00-$-40K-$-460K-$-230K
Common stock issued$0.00$290K$0.00$0.00$1.25M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.16B$290K-$-50K$110K$1.19M
Net change in cash-$-758.02M-$-2.31M-$-4.72M$5.45M-$-110K
Cash at end of period$1.03B$1.78M$4.09M$8.81M$3.35M
Operating cash flow-$-1.92B-$-2.6M-$-4.63M$5.8M-$-1.07M
Capital expenditure$0.00$0.00-$-10K-$-260K-$-230K
Free cash flow-$-1.92B-$-2.6M-$-4.64M$5.54M-$-1.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About 20/20 Biolabs Inc.

        20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.

        CEO
        Jonathan Cohen
        Employees
        14
        Beta
        1.54

        Explore

        Frequently asked questions

        What is the intrinsic value of 20/20 Biolabs Inc. (AIDX)?

        InvestorsCraft does not currently publish an intrinsic value for AIDX. How the IC value is calculated.

        Is AIDX undervalued?

        InvestorsCraft does not publish an undervaluation signal for AIDX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.